Axillary Adenopathy Reported After Recent COVID-19 Vaccination
Management approach to these findings includes axillary ultrasound if clinical concern persists six weeks after final dose of vaccine
Diagnostic Testing
Symptoms ID’d That Should Trigger COVID-19 Testing
Testing people with any of seven key symptoms in the first three days of illness would detect 96 percent of symptomatic cases
Walgreens to Sell Labcorp COVID-19 Test Home Collection Kit in Stores
This kit will be Walgreens first OTC COVID-19 testing option available for purchase in-store at the pharmacy counter.
ExEm Foam Now Available for Ultrasound Tubal Patency Testing
ExEm Foam is indicated for sonohysterosalpingography to assess fallopian tube patency in women with known or suspected infertility.
USPSTF Advises Against Screening for Asymptomatic Carotid Artery Stenosis
USPSTF reaffirms 2014 stance of D recommendation because harms of screening for asymptomatic CAS outweigh the benefits
US Awards Contract for COVID-19 Home Test Kit
With the product from Australian company Ellume, users can swab themselves at home and check their status in about 20 minutes
BinaxNOW Rapid Antigen Test Has Lower Sensitivity Than RT-PCR
Sensitivity 64.2 and 35.8 percent for specimens from symptomatic and asymptomatic persons, with near 100 percent specificity
MPR Weekly Dose Podcast Episode 64
This week we have news of the neutralizing response of the Pfizer-BioNTech vaccine to the new COVID-19 variant; A trial investigated ravulizumab in adults with severe COVID is halted; A rapid blood test for concussions gets the all clear; A novel treatment for chronic kidney disease in patients with type 2 diabetes; And the drug manufacturer Fresenius Kabi announces a voluntary recall of one lot of an NSAID treatment.
FDA Clears Rapid Blood Test for Mild Traumatic Brain Injury
The test measures glial fibrillary acidic protein and ubiquitin carboxyl-terminal hydrolase L1, biomarkers present in blood plasma at elevated concentrations after a brain injury.
FDA: SARS-CoV-2 Mutations May Impact Molecular Tests
The FDA is alerting clinical laboratory staff and health care providers regarding the risk of false negative results with any SARS-CoV-2 test if a mutation occurs in the part of the virus’ genome assessed by that test.
